These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 12422697)
21. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Conte P; Guarneri V Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427 [TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Doggrell SA Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424 [TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy of bone metastases in breast cancer patients. Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337 [TBL] [Abstract][Full Text] [Related]
24. On the horizon: can bisphosphonates prevent bone metastases? Coleman R Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867 [TBL] [Abstract][Full Text] [Related]
25. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases. Serefoglu EC; Balbay MD Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241 [TBL] [Abstract][Full Text] [Related]
26. Home infusions of biphosphonate in cancer patients: a prospective study. Italiano A; Ciais C; Chamorey E; Marcy PY; Largillier R; Ferrero JM; Thyss A J Chemother; 2006 Apr; 18(2):217-20. PubMed ID: 16736892 [TBL] [Abstract][Full Text] [Related]
27. Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy. Osanai T; Tsuchiya T; Sugawara M J Orthop Sci; 2009 Mar; 14(2):224-7. PubMed ID: 19337817 [No Abstract] [Full Text] [Related]
28. Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Diel IJ; Bergner R Oncologist; 2005 Jan; 10(1):82-3; author reply 84-7. PubMed ID: 15632256 [No Abstract] [Full Text] [Related]
29. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Balla J Oncologist; 2005 May; 10(5):306-8; author reply 311-2. PubMed ID: 15851781 [No Abstract] [Full Text] [Related]
30. Breast cancer and osteolytic metastases: can bisphosphonates help? Siris ES Nat Med; 1997 Feb; 3(2):151-2. PubMed ID: 9018229 [No Abstract] [Full Text] [Related]
31. The management of skeletal metastases. Galasko CS J R Coll Surg Edinb; 1980 May; 25(3):144-61. PubMed ID: 6452521 [No Abstract] [Full Text] [Related]
32. [The efficacy of pamidronate in reducing skeletal associated events in patients with advanced multiple myeloma]. Adamietz IA Strahlenther Onkol; 1997 Jan; 173(1):52-3. PubMed ID: 9082587 [No Abstract] [Full Text] [Related]
33. [Modern approaches to the prophylactic treatment of metastatic lesions]. Solini A; Guercio N; Paschero B; Ruggieri N Chir Organi Mov; 1986; 71(3):217-26. PubMed ID: 3803005 [No Abstract] [Full Text] [Related]
34. Diagnosis and referral of adults with suspected bony metastases. Downie S; Bryden E; Perks F; Simpson AHR BMJ; 2021 Jan; 372():n98. PubMed ID: 33495231 [No Abstract] [Full Text] [Related]
35. New clinical studies open to patients experiencing bone pain. Liles TM Oncol Nurs Forum; 1998 Jul; 25(6):975. PubMed ID: 9679250 [No Abstract] [Full Text] [Related]
36. Letter: Use of L-dopa to relieve pain from bone metastases. Nixon DW N Engl J Med; 1975 Mar; 292(12):647. PubMed ID: 1113750 [No Abstract] [Full Text] [Related]
37. CORR (®) Tumor Board: Is Prophylactic Intervention More Cost-Effective than the Treatment of Pathologic Fractures in Metastatic Bone Disease? Anderson ME; Wu JS; Vargas SO Clin Orthop Relat Res; 2016 Jul; 474(7):1560-2. PubMed ID: 27172817 [No Abstract] [Full Text] [Related]